Join us for our next exclusive masterclass designed for innovators and entrepreneurs in the health tech sector. This session is designed to assist you in gaining clarity on how to be attractive to Venture Capital and other investors and how to be prepared once you get that first meeting.

During this session, you'll delve into the details of what it means to be "investment ready", including how to present the maturity of your technology, business operations, clinical pathways and applications, and your iIP strategy and position. We'll also explore what the typical process of venture capital funding looks like, and what to expect at the different stages before you can close a funding round.

What You Will Learn:

When to look for funding: when is the right time to start engaging with investors and who to talk to first?
Value proposition: how to clearly articulate your value proposition and commercial potential so you get invited to the next stage of the funding process.
What are the investors looking for: get clarity on the criteria that assessors use when deciding whether or not you are a good fit for their fund.
Obtaining funding: Strategies for making the whole funding process as smooth as possible for both you and the investor

Who Should Attend:

This masterclass is designed for entrepreneurs, researchers, and professionals in the health tech sector who are at the early stages of commercialisation (TRL1-5) and are ready to seek investor funding for their projects or companies.

Meet the Experts:

Prashanth Rajan, Brandon Capital

Prashanth offers invaluable perspectives on the investment process and how to tailor your approach to meet investor expectations. He will help you learn about what life sciences VCs look for in opportunities, receive feedback on commercialisation strategy, development plans, and commercialisation grant opportunities such as CUREator plus.

Brandon BioCatalyst, Australia’s leading life sciences VC, manages over $800 million and actively supports more than 30 companies in therapeutics, devices, diagnostics, and digital health sectors.

Rob McInnes, Sydney Angels

Sydney Angels is a not-for-profit angel investment membership organisation. It is led by an elected committee.

Liza Yeo, Uniseed

Uniseed, Australia's longest-standing venture fund, collaborates with partner research organizations and UniSuper to invest in innovative ventures, managing funds such as Fund-3 and a Follow-on Fund, and expanding partnerships with universities, while also garnering praise from researchers and CEOs of its startups for its supportive environment.

**Lunch will be provided

Cicada Innovations is proud to be collaborating with the Westmead Health & Innovation District, Australia’s fastest-growing health and innovation precinct, for this commercialisation masterclass series. These masterclasses are to help bridge the gap between research and commercialisation.

Find out more about the Cicada HealthTech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.